Related Experiment Video
Updated: Aug 22, 2025

11:29
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
10.9K
The Potential of MicroRNAs as Non-Invasive Prostate Cancer Biomarkers: A Systematic Literature Review Based on a
Emilia Bevacqua1, Salvatore Ammirato2, Erika Cione1
1Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.
Cancers
|November 11, 2022
Summary
This study reviews microRNAs (miRs) as potential biomarkers for prostate cancer (PCa) diagnosis. Urine-based miR detection shows promise as a reliable, non-invasive tool for PCa detection, offering an alternative to the less specific prostate-specific antigen (PSA) test.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Research
Background:
- Prostate cancer (PCa) is a leading cause of cancer death in men.
- The prostate-specific antigen (PSA) test has limitations, including high false-positive rates.
- MicroRNAs (miRs) are emerging as promising biomarkers for PCa diagnosis and prognosis.
Purpose of the Study:
- To consolidate the current state-of-the-art research on microRNAs as biomarkers for prostate cancer.
- To analyze and discuss the existing literature on miRs in PCa using a systematic review and text mining approach.
Main Methods:
- A Systematic Literature Review (SLR) was conducted.
- Text mining using the Latent Dirichlet Allocation (LDA) algorithm was applied to analyze 213 publications.
- Research was organized into three key topics using the MySLR digital platform.
Main Results:
- Identified three main topics within the research area of miRs and PCa.
- Several miRs were found to be associated with prostate cancer progression.
- Detection of miRs in urine emerged as a promising non-invasive diagnostic tool.
Conclusions:
- MicroRNAs hold significant potential as diagnostic and prognostic biomarkers for prostate cancer.
- Urine-based microRNA detection represents a reliable and non-invasive approach for PCa diagnosis.
- Further research is recommended to advance the field of microRNA-based PCa diagnostics.

